Personalis Inc (PSNL)

$7.51 -0.09 (-1.18%)
Market Cap 674.91M
Revenue (ttm) 84.61M
Net Income (ttm) -81.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.06%
Debt to Equity Ratio 0.00
Volume 1,126,900
Avg Vol 1,260,076
Day's Range N/A - N/A
Shares Out 88.80M
Stochastic %K 27%
Beta 1.92
Analysts Strong Sell
Price Target $11.00

Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor an...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 752 1300
Fax: 650 752 1301
Address:
6600 Dumbarton Circle, Fremont, United States
ExNoose
ExNoose Nov. 14 at 11:12 PM
$PSNL T. ROWE PRICE added 1.6M shares on that dip. In a few months we ll find out who added on that dip as well before we leave the single digits for good.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 10:02 PM
💎 LiquidTheta® Live Actionable Trade Asset: $PSNL Contracts: $PSNL April 17, 2026 $10 Calls Scale in: $1.56- $1.91 Scale out: $6.08-$10.43 Profit Potential : 339% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:22 PM
Hedge Alert Live - Protect Your Portfolio Contract: $PSNL $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.36 - $0.80 Exit Price Target: $0.81 Profit Margin: +124% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
marcopol0
marcopol0 Nov. 14 at 5:10 PM
$PSNL I hear we’re pinned down at this level until Nov 21 options expiry. Is that a possibility?
0 · Reply
MD109
MD109 Nov. 14 at 3:51 PM
$PSNL Increased my position this morning. Will buy more if the market continues to drag the share price down into bargain territory.
1 · Reply
ExNoose
ExNoose Nov. 14 at 11:12 AM
$PSNL Where we were, where we are and you can imagine where we going....
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:41 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PSNL $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.36 - $0.80 Exit Price Target: $0.67 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
magnitudeFC
magnitudeFC Nov. 13 at 5:10 AM
$PSNL is the reason for the muted response to approval that we got reimbursement only for 2 tests a year vs 4 test per year as some were hoping for? Kinda surprised the market has shrugged this off. Yes I also appreciate the stock is up a lot from the lows so maybe it was priced in, but im curious for your opinions.
2 · Reply
Skibum77
Skibum77 Nov. 12 at 10:13 PM
$PSNL well if Chris cares about the stock price, I would expect a update on the traction. Tempus is gaining and the amount of tests they have started to sell after getting the reimbursement News, but I’m not holding my breath. 
1 · Reply
degeneratetrader23
degeneratetrader23 Nov. 12 at 8:57 PM
$PSNL wtf?
1 · Reply
Latest News on PSNL
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Nov 10, 2025, 9:00 AM EST - 4 days ago

Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 9:46 PM EST - 10 days ago

Personalis, Inc. (PSNL) Q3 2025 Earnings Call Transcript

Personalis Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 10 days ago

Personalis Reports Third Quarter 2025 Financial Results

Personalis to Announce Third Quarter 2025 Financial Results

Oct 21, 2025, 4:01 PM EDT - 24 days ago

Personalis to Announce Third Quarter 2025 Financial Results

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Oct 16, 2025, 9:00 AM EDT - 4 weeks ago

Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 15, 2025, 5:35 PM EDT - 2 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Sep 10, 2025, 4:05 PM EDT - 2 months ago

CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Sep 3, 2025, 4:05 PM EDT - 2 months ago

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis to Participate in Upcoming Investor Conferences

Aug 27, 2025, 4:01 PM EDT - 2 months ago

Personalis to Participate in Upcoming Investor Conferences

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Aug 6, 2025, 8:11 AM EDT - 3 months ago

Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

SMCI

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:49 PM EDT - 3 months ago

Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript

Personalis Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 4:01 PM EDT - 3 months ago

Personalis Reports Second Quarter 2025 Financial Results

Personalis to Announce Second Quarter 2025 Financial Results

Jul 22, 2025, 4:01 PM EDT - 4 months ago

Personalis to Announce Second Quarter 2025 Financial Results

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

Jul 9, 2025, 4:00 PM EDT - 4 months ago

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

TEM

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 3, 2025, 4:00 PM EDT - 5 months ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Jun 2, 2025, 4:00 PM EDT - 5 months ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 22, 2025, 6:00 AM EDT - 6 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 14, 2025, 4:01 PM EDT - 6 months ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:41 PM EDT - 6 months ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

Personalis Reports First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 6 months ago

Personalis Reports First Quarter 2025 Financial Results

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 28, 2025, 5:00 PM EDT - 7 months ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 4:01 PM EDT - 7 months ago

Personalis to Announce First Quarter 2025 Financial Results

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Apr 22, 2025, 6:00 AM EDT - 7 months ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 4:01 PM EDT - 8 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Mar 3, 2025, 6:00 AM EST - 9 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 7:40 PM EST - 9 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:01 PM EST - 9 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 9 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 18, 2025, 4:01 PM EST - 9 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 14, 2025, 10:50 AM EST - 9 months ago

Exciting Technology At Personalis, But Profitability Eludes Them

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 4:01 PM EST - 9 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 28, 2025, 4:01 PM EST - 10 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 13, 2025, 5:00 AM EST - 10 months ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Jan 7, 2025, 4:01 PM EST - 11 months ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 19, 2024, 9:00 AM EST - 11 months ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Personalis and Tempus Expand Collaboration to Biopharma

Dec 16, 2024, 8:00 AM EST - 11 months ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Personalis to Participate at Upcoming Investor Conferences

Nov 20, 2024, 4:01 PM EST - 1 year ago

Personalis to Participate at Upcoming Investor Conferences

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:11 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Personalis Reports Third Quarter 2024 Financial Results

Nov 6, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Third Quarter 2024 Financial Results

Personalis to Present at the Stifel 2024 Healthcare Conference

Nov 5, 2024, 4:01 PM EST - 1 year ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Personalis to Announce Third Quarter 2024 Financial Results

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Third Quarter 2024 Financial Results

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Sep 16, 2024, 9:00 AM EDT - 1 year ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 18, 2024, 7:47 AM EDT - 1 year ago

Personalis: Resetting My Strategy Following The Q2 Beat

Personalis and Tempus Announce Expanded Collaboration

Aug 16, 2024, 8:30 AM EDT - 1 year ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 11:09 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Personalis Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports Second Quarter 2024 Financial Results

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 31, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Personalis to Announce Second Quarter 2024 Financial Results

Jul 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce Second Quarter 2024 Financial Results

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Jun 18, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

Jun 13, 2024, 8:00 AM EDT - 1 year ago

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

ExNoose
ExNoose Nov. 14 at 11:12 PM
$PSNL T. ROWE PRICE added 1.6M shares on that dip. In a few months we ll find out who added on that dip as well before we leave the single digits for good.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 10:02 PM
💎 LiquidTheta® Live Actionable Trade Asset: $PSNL Contracts: $PSNL April 17, 2026 $10 Calls Scale in: $1.56- $1.91 Scale out: $6.08-$10.43 Profit Potential : 339% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:22 PM
Hedge Alert Live - Protect Your Portfolio Contract: $PSNL $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.36 - $0.80 Exit Price Target: $0.81 Profit Margin: +124% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
marcopol0
marcopol0 Nov. 14 at 5:10 PM
$PSNL I hear we’re pinned down at this level until Nov 21 options expiry. Is that a possibility?
0 · Reply
MD109
MD109 Nov. 14 at 3:51 PM
$PSNL Increased my position this morning. Will buy more if the market continues to drag the share price down into bargain territory.
1 · Reply
ExNoose
ExNoose Nov. 14 at 11:12 AM
$PSNL Where we were, where we are and you can imagine where we going....
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:41 AM
Hedge Alert Live - Protect Your Portfolio Contract: $PSNL $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.36 - $0.80 Exit Price Target: $0.67 Profit Margin: +85% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
magnitudeFC
magnitudeFC Nov. 13 at 5:10 AM
$PSNL is the reason for the muted response to approval that we got reimbursement only for 2 tests a year vs 4 test per year as some were hoping for? Kinda surprised the market has shrugged this off. Yes I also appreciate the stock is up a lot from the lows so maybe it was priced in, but im curious for your opinions.
2 · Reply
Skibum77
Skibum77 Nov. 12 at 10:13 PM
$PSNL well if Chris cares about the stock price, I would expect a update on the traction. Tempus is gaining and the amount of tests they have started to sell after getting the reimbursement News, but I’m not holding my breath. 
1 · Reply
degeneratetrader23
degeneratetrader23 Nov. 12 at 8:57 PM
$PSNL wtf?
1 · Reply
GGator
GGator Nov. 12 at 8:09 PM
$PSNL For those of you claiming that they didn’t promote this on social media…here is Twitter from 2 days ago. Come on guys.
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 12 at 5:19 PM
💎 LiquidTheta® Live Actionable Trade Asset: $PSNL Contracts: $PSNL April 17, 2026 $10 Calls Scale in: $1.54- $1.88 Scale out: $5.99-$10.27 Profit Potential : 443% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
arribaStocktrading
arribaStocktrading Nov. 12 at 3:45 PM
$PSNL The Market Makers can whip this around on low-volume and stick money in their pockets. It's like living with termites - they are not just facilitators of trading but active predators.
1 · Reply
ExNoose
ExNoose Nov. 11 at 9:51 PM
$PSNL shorts covered 600k more shares when we we at $10, end of last month.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 11 at 9:06 PM
💎 LiquidTheta® Live Actionable Trade Asset: $PSNL Contracts: $PSNL April 17, 2026 $10 Calls Scale in: $1.82- $2.23 Scale out: $7.09-$12.15 Profit Potential : 388% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
BeeDecay
BeeDecay Nov. 11 at 7:37 PM
$PSNL Busy period, not that much time looking into stuff but am I right to say management did NOT provide a press release? When visiting the Personalis website I see the headline, but when clicking on it I am directed to the https://www.genomeweb.com/ website which requires to set up an account? This news should be spread without barriers. Actively. Broadly. I want Hall to explain this is a transformative event for the company. I want him to explain what it means for revenues. What it means retro actively, too -- how many tests during the last 9 months will now be in the books? I see nothing of that. And that's yet another bummer -- after the questionable explanation about pushing the brake last Q wrt getting as much tests performed as possible. Another missed opportunity imho... Happy with the technology. Not so happy with management. Feel free to comment.
4 · Reply
BeeDecay
BeeDecay Nov. 11 at 7:28 PM
$PSNL Well, $XBI is up 3% today...
0 · Reply
Penki1985
Penki1985 Nov. 11 at 6:26 PM
$PSNL So we crawled back into the wedge. Now what?
1 · Reply
DARKP00L
DARKP00L Nov. 11 at 5:15 PM
$PSNL 11:54 on Nov. 11 2025 Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $9 #tradeideas
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:55 PM
Morgan Stanley has adjusted their stance on Personalis ( $PSNL ), setting the rating to Equal-Weight with a target price of 5 → 9.
1 · Reply
MD109
MD109 Nov. 11 at 4:04 PM
$PSNL The positive reimbursement news has significantly de-risked Personalis. It took about 6 months for this decision because MolDx did a very deep dive into the tech. I expect the review process for lung cancer and IO therapy monitoring to be shorter and to propel the stock much higher. I hold a very large position in the company and I am now planning on purchasing more shares. I feel that being able to buy shares in the single digits post reimbursement is a great opportunity for new investors to enter and existing shareholders to upsize their position.
2 · Reply
Iightning
Iightning Nov. 11 at 4:02 PM
1ightning® Options Trade Alert (Actionable) | Buy $PSNL Nov 21 $10 Call | Enter: $0.39 Exit: $0.57 | Profit: 44.50% ROI | https://1ightning.com
0 · Reply